发明名称 |
Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
摘要 |
<p>The present invention provides novel highly sialylated Fc-EPO fusion proteins preferably comprising a couple of modifications in the Fc- portion as well as in the EPO portion and having improved pharmacokinetics. Specifically, the Fc-EPO proteins have a prolonged serum half-life and increased in vivo potency. The Fc-EPO fusion proteins synthesized in BHK cells have dramatically prolonged serum half-lives and increased in vivo potency when compared to corresponding Fc-EPO fusion proteins produced in other cell lines, such as, for example, NS/O cells.</p> |
申请公布号 |
WO2005063808(A1) |
申请公布日期 |
2005.07.14 |
申请号 |
WO2004EP14608 |
申请日期 |
2004.12.22 |
申请人 |
MERCK PATENT GMBH;GILLIES, STEPHEN, D.;LAUDER, SCOTT |
发明人 |
GILLIES, STEPHEN, D.;LAUDER, SCOTT |
分类号 |
A61K38/00;A61K38/18;C07K14/505;(IPC1-7):C07K14/505 |
主分类号 |
A61K38/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|